Clinical update of medications associated with QT prolongation among COVID-19 patients

Authors : Ernest HERBERT, Dominique FOURNİER

Pages : 732-741

Doi:10.18621/eurj.1102545

View : 9 | Download : 8

Publication Date : 2022-09-04

Article Type : Review Paper

Abstract :In the struggle against COVID-19 pandemic, chloroquine insert ignore into journalissuearticles values(CQ); insert ignore into journalissuearticles values(a 4-aminoquinoline); and its derivative hydroxychloroquine insert ignore into journalissuearticles values(HCQ); have both been used as a potential form of treatment among infected patients. Originally known as an antimalarial quinolone, many countries have adopted their use as an option to treat COVID-19 patients. In humans, dose-dependent chloroquine induces QT interval prolongation. It also blocks the human ether-a-go-go-related gene insert ignore into journalissuearticles values(hERG);, which encodes the rapidly activating delayed rectifier K+ channel. The action potential duration is then prolonged, as the eventual QTc interval of the electrocardiogram insert ignore into journalissuearticles values(ECG);, resulting in torsade de pointes and cardiac arrhythmias that could lead to sudden death. It is yet unknown whether COVID-19 itself has any effect on the QTc interval. The current review established what is new and different from other studies involving the use of chloroquine and hydroxychloroquine among COVID-19 patients plus the corresponding QT interval prolongation in affected individuals.
Keywords : Long QT prolongation, hERG, ionic channels, drug repurposing, mobile devices, SARS CoV 2